ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2012
Examination of Smad2 and Smad4 copy-number variations in skin cancers.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Methylation status, mRNA and protein expression of the SMAD4 gene in patients with non-melanocytic skin cancers.Molecular biology reports · 2023Article
- TGFβ Signaling in Photoaging and UV-Induced Skin Cancer.The Journal of investigative dermatology · 2021Review
- Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis.Nature communications · 2015Article
- Contribution of glutathione S-transferase gene polymorphisms to development of skin cancer.International journal of clinical and experimental medicine · 2015Article
- Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.ISRN dermatology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmad2 and Smad4 transcription factors were identified as the signalling mediators of transforming growth factor Β (TGF Β) pathway. Copy number variations (CNVs) have been discovered to have phenotypic consequences and be associated with various types of cancers. CNVs of Smad2 and Smad4 were found to be associated with cancer pathogenesis in the recent array-based study. However, no such study has been performed in skin cancer yet. In this study, we aim to examine the CNVs of Smad2 and Smad4 in skin samples.
methodsA total of 195 paired samples including basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and actinic keratosis (AK) were included. Real-time PCR was used for the quantification of Smad2 and Smad4 copy numbers.
resultsCNVs of Smad2 showed statistical differences between cancer samples (both SCC and BCC) and normal tissues (p<0.05). For Smad4, statistical difference was observed only in SCC samples (p=0.014), but not in BCC and AK samples (p=0.173 and 0.314, respectively). Association analysis showed that the frequencies of Smad2 and Smad4 CNVs were correlated with the severity of skin abnormalities (p=0.002 for Smad2 and p=0.029 for Smad4).
conclusionsCNVs of Smad2 are associated with SCC and BCC, while CNVs of Smad4 are associated with SCC but not BCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.